STOCK TITAN

Insider Notice: IDXX 407 Shares to be Sold via Morgan Stanley on NASDAQ

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for IDEXX Laboratories (IDXX) reports a proposed sale of 407 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $264,533.53. The filing lists the company's outstanding shares as 80,004,694, so the proposed sale represents approximately 0.00051% of outstanding stock. The acquisition history provided shows the shares originated from multiple Employee Stock Purchase Plan purchases and a Restricted Stock grant, with acquisition dates ranging from 06/30/2021 through 03/29/2024. The filer certifies they are not aware of undisclosed material adverse information and uses Morgan Stanley as the executing broker. The proposed approximate sale date is 08/12/2025.

Positive

  • Complete disclosure of broker, exchange, proposed sale date, and aggregate market value
  • Acquisition history provided showing Employee Stock Purchase Plan and Restricted Stock origins
  • Filer certification that no undisclosed material adverse information is known

Negative

  • None.

Insights

TL;DR: Small insider sale notice: 407 shares valued at $264,533.53—negligible versus 80,004,694 outstanding shares.

The Form 144 documents a planned sale under Rule 144 for 407 common shares using Morgan Stanley as broker with an aggregate value of $264,533.53. Given the stated 80,004,694 shares outstanding, the sale equals roughly 0.00051% of the float, indicating the transaction is immaterial to company capital structure. The filing includes a clear acquisition record showing multiple Employee Stock Purchase Plan purchases and a Restricted Stock grant, and the filer affirms no undisclosed material adverse information. From a market-impact perspective, the notice signals compliance rather than a material shift in ownership.

TL;DR: Compliance-focused filing: disclosure of provenance and broker details; sale size is trivial relative to outstanding shares.

The Form 144 provides the necessary disclosure elements: broker name (Morgan Stanley Smith Barney LLC), exchange (NASDAQ), proposed sale date (08/12/2025), and a detailed acquisition history (ESPP and Restricted Stock entries). The filer also makes the standard certification regarding material non-public information. These items demonstrate adherence to disclosure rules for an insider sale; nothing in the filing raises governance or compliance concerns based on the information presented.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the IDEXX (IDXX) Form 144 report?

The filing reports a proposed sale of 407 common shares valued at $264,533.53 to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.

When is the proposed sale date on the IDXX Form 144?

The approximate date of sale listed in the notice is 08/12/2025.

How significant is the proposed sale relative to IDEXX's outstanding shares?

The filing lists 80,004,694 shares outstanding; the proposed sale of 407 shares represents about 0.00051% of that total.

What is the origin of the shares being sold in the IDXX Form 144?

The acquisition table shows most shares came from multiple Employee Stock Purchase Plan purchases and one Restricted Stock grant, with acquisition dates between 06/30/2021 and 03/29/2024.

Who is the executing broker named in the Form 144 for IDXX?

The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, 8th Floor, New York, NY 10004.
IDEXX Laboratories

NASDAQ:IDXX

IDXX Rankings

IDXX Latest News

IDXX Latest SEC Filings

IDXX Stock Data

54.95B
79.30M
0.68%
97.52%
2.56%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
WESTBROOK